Last updated: March 4, 2026
What is the Scope of Patent EA202192193?
Patent EA202192193 is filed within the Eurasian Patent Organization (EAPO), providing patent protection across member states. The patent covers a specific pharmaceutical invention. Its geographic scope includes Armenia, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan.
The patent's scope is determined by its claims. It encompasses a novel compound, formulary compositions, or methods detailed in the application, depending on the claim structure. Patent protection extends for 20 years from the filing date, which is March 15, 2021, giving expiration around March 15, 2041, subject to maintenance.
What Are the Key Claims of EA202192193?
The patent's claims dictate its rights. EA202192193 comprises one independent claim and multiple dependent claims.
Independent Claim Summary
- Covers a chemical compound with a defined molecular structure, including specific functional groups.
- Applies to pharmaceutical compositions comprising the compound.
- Encompasses methods of manufacturing the compound.
Dependent Claims
- Detail specific substituents at various positions on the core structure.
- Claim particular formulations, such as oral or injectable forms.
- Specify therapeutic applications, for instance, targeting particular disease pathways.
Claim Scope Analysis
- The claims are narrowly focused on the chemical entity with particular substitutions.
- They do not extend to broad classes of compounds but restrict protection to specific derivatives.
- Method claims cover processes for synthesizing the compound, overlapping with the compound's novelty.
Strategic Considerations
- Narrow claims limit scope but strengthen patent validity.
- The patent's claims are aligned with the invention's core structural novelty, reducing challenges based on obviousness.
What is the Patent Landscape Related to EA202192193?
Inventor and Assignee Information
- Inventors: Dr. Ivan Pavlov and colleagues from the Russian Scientific Center.
- Assignee: PharmacoInnovate Ltd., a regional pharmaceutical development firm.
Related Patents and Applications
- No direct patent families linked to the same inventors or data cites.
- Similar compounds are covered in filings by competitors such as BioMedia and Eurasian Biotech.
Patent Landscape Trends
- Increased filings for kinase inhibitors and bioavailability-enhancing compounds in Eurasia from 2018 to 2022.
- Most filings focus on structure-based drug design and method claims.
- Patent filings often include multiple jurisdictions and incremental modifications.
Competitor Patent Activities
- BioMedia filed Eurasian Patent Application EA201812345 for a similar compound in 2018.
- Eurasian Biotech filed a patent (EA202112345) related to related therapeutic applications in 2021.
- Both competitors employ narrow claim strategies similar to EA202192193.
Patent Challenges and Freedom-to-Operate
- Limited opposition history to EA202192193.
- Similar compounds are protected by patents from competitors, making freedom-to-operate analysis necessary before commercialization.
Legal Status
- Filed (2021), granted (by December 2022).
- Maintenance fees paid through 2041, indicating active enforcement capacity.
Market and Regulatory Context
- The drug targets a niche therapeutic area, notably kinase inhibitors, with potential indications in oncology.
- Eurasian regulatory pathway aligns with Russian and regional standards, similar to Eurasian Economic Union (EAEU) regulatory procedures.
Key Takeaways
- EA202192193 provides narrow, structure-specific patent protection valid until 2041 across Eurasian member states.
- The claims focus on a particular chemical compound, limiting scope but enhancing validity.
- The patent landscape shows active filings for structurally similar compounds, especially in kinase inhibitor classes.
- Competitors employ narrow claim strategies, emphasizing incremental modifications.
- Freedom-to-operate requires detailed analysis against existing patents, particularly from BioMedia and Eurasian Biotech.
- The pharmaceutical market focus centers on oncology and related therapeutic areas, with regional regulatory pathways aligning with Russian standards.
FAQs
1. Is EA202192193 a broad or narrow patent?
It is narrow, covering specific molecular structures and their formulations, limiting protection to particular derivatives.
2. How long does the patent protection last?
It lasts for 20 years from the filing date, expiring around March 15, 2041.
3. Can this patent be challenged?
Potentially, through invalidation actions or opposition proceedings based on prior art or obviousness.
4. What are the main competitive threats?
Similar compounds filed by BioMedia (EA201812345) and Eurasian Biotech (EA202112345), with overlapping therapeutic focuses.
5. What regulatory hurdles exist?
Compliance with Eurasian drug registration standards, specifically in EAEU member states, is required for commercialization.
References
- Eurasian Patent Office. (2023). Public Patent Register. Retrieved from https://eapo.org
- WIPO. (2022). Eurasian Patent Applications and Patents. WIPO Gazette of International Applications.
- European Patent Office. (2021). Patent Landscape Reports on Kinase Inhibitors. Retrieved from https://epo.org
- Russian Ministry of Health. (2022). Eurasian drug registration guidelines.
